Genzyme CorporationFebruary 14, 2025

FDA 483 - Genzyme Corporation - February 14, 2025

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Genzyme Corporation

Record Details

An FDA inspection of Genzyme Corporation's Northborough, MA facility revealed three observations related to labeling, packaging, and quality control. The firm failed to follow procedures for correct drug product labeling, resulting in incorrect potency values printed on Altuviiio finished product. Additionally, examination of packaging materials was not adequately performed, and investigations into unexplained discrepancies were not consistently documented.

Company: Genzyme Corporation
Inspection Date: February 14, 2025
Product Type: Biologics
Office: New England District Office
People: Priscilla M. Pastrana (investigator)
Lizaida Perez (FDA_PERSONNEL)

Open in Dashboard

ID · 3adce78e-cce8-40f0-a243-541478a76c60